on the west side of Chicago, IL. Institutional Review Board approval was obtained at both sites; all participants provided informed consent.
FMECA is an engineering method typically used to identify safety vulnerabilities in products and processes before they are produced or implemented, 16, 17 particularly in high-risk industries, such as air carrier and nuclear power. It has increasingly been applied to understand vulnerabilities and to improve patient safety in healthcare because the Joint Commission requires US hospitals seeking accreditation to perform at least 1 risk assessment annually. 18, 19 FMECAs help to counter most organizations' common temptation to focus on system or process solutions for the most evident and visible failures rather than the most critical, which may not be the same. Most importantly, it can also be used in an iterative manner to support process redesign to insure the effectiveness of the safety intervention(s) and to assess the impact of implementation. 20 In our study, unique FMECA elements included (1) multidisciplinary meetings with teams of clinicians and staff who are involved in and knowledgeable about acute stroke care; (2) FMECA facilitation and analysis by risk assessment experts (Holl, Khare, Khorzad); and (3) use of operational data to enhance the robustness of the ranking of identified failures. Specific FMECA steps included (1) defining the boundaries of the topic (ie, beginning at arrival of a patient with AIS in the ED and ending with intravenous tPA administration); (2) assembling a team of clinicians and staff who are involved in acute stroke care in each hospital's ED; (3) graphically describing the process by having the stroke team members describe, in their own words, each step in the processes and systems of DTN care; and (4) conducting the criticality analysis and risk ranking by evaluating each failure's frequency, impact to the patient (severity), causes, and existing safeguards using standardized scoring tools. 21, 22 Participants On the basis of input from each site's stroke program coordinator, we used convenience sampling to invite AMC and CH clinicians and staff involved in DTN care (ie, ED clinicians and staff, representatives from neurology, pharmacy, radiology, laboratory, and process improvement departments) to participate in 2 moderated sessions at their respective hospital, each lasting ≈2 hours. Specifically, AMC participants included the stroke program coordinator, 2 neurologists (resident and attending), 3 radiologists (resident, administrator, and attending), 6 emergency medicine physicians/staff (2 residents, 1 attending, and 3 nurses), 2 pharmacists, and 1 process improvement leader (15 total) . At the CH, participants included the stroke program coordinator, telemetry director, emergency medical services (EMS) coordinator, laboratory supervisor, computed tomography (CT) supervisor, pharmacist, quality manager, and an ED attending physician (8 total) . Participants received modest remuneration in the form of a $20 gift card for each session.
Operational Data
Data on various performance measures and times of stroke care were obtained from institutional process improvement leaders and stroke program coordinators and from each hospital's Get With The Guidelines-Stroke registry. All time data were captured using timestamps whenever possible, including (1) door time (using ED triage registration time), (2) CT imaging time (using automated timestamps in the CT scanners), (3) first evaluation time (using time-stamped nursing notes), and (4) thrombolytic treatment time (using nursing documentation on medication administration sheet or hospital electronic record of bolus administration as needle time).
FMECA Sessions
Sessions were scheduled in advance and several weeks apart to ensure good participation at both meetings. Sequenced sessions were conducted at the AMC and CH (ie, December 20, 2013 and January 10, 2014 [AMC] and November 13, 2014 and December 11, 2014 [CH]). Follow-up, key informant interviews with participants were conducted, as necessary, to clarify gaps in the risk scores and ranking of high severity failures. Each session was audiotaped for post hoc review and process map development. Five phases of AIS care were predefined: (1) patient prearrival, (2) arrival to ED (door), (3) initial assessment, (4) diagnosis, and (5) treatment (needle).
In the first session, participants were asked to describe their individual role, tasks, and activities when providing care for patients with AIS, between ED arrival and tPA administration (DTN time). Participants were also asked to describe and comment on any workarounds or shortcuts used for existing protocols. During this session, field notes were kept by research staff (Brown, Nannicelli) and each reported step in the DTN process was recorded using sticky notes to graphically map the DTN process comprehensively. Subsequently, the notes and description were used to create a detailed, site-specific DTN process map of all identified steps (Microsoft Visio 2013; Microsoft Corporation, Redmond, WA); participants reviewed and corrected the process map before the second session (Figures I and II in the Data Supplement). Once finalized, the map was used to develop a risk table to score each process step.
During the second session, participants received copies of the process map, risk table, and standardized FMECA risk assessment scoring matrix 21 (Figure) . Participants were then asked, for each step, to (1) systematically review and identify potential vulnerabilities or failures and their causes, (2) estimate and score the frequency of each failure, (3) estimate and score the severity (harm to the patient) of each failure, and (4) identify and score the strength of existing safeguards to mitigate the identified failures. When available, the research team used empirical or operational data to estimate and score the frequency of a failure.
On the basis of the scores, we calculated a risk priority number (product of frequency, severity, and strength of safeguard) and a criticality number (product of frequency by severity) for each failure in the DTN process. Failures were then ranked with the highest scores representing the most critical failures in DTN care. We then compared the most critical failures between the 2 hospitals. 23, 24 
Results
At baseline, both AMC and CH DTN data showed that, respectively, 75.7% (28/37; median: 46 minutes) and 68.0% (17/25; median: 57 minutes) of patients met the goal of DTN ≤60 minutes in the preceding 12 months. Compared with the AMC, there were less healthcare providers involved in acute stroke
WHAT IS KNOWN
• The benefit of intravenous tissue-type plasminogen activator for ischemic stroke is time-dependent such that earlier treatment leads to better functional outcomes. • Efforts to reduce delays in time to treatment with tissue-type plasminogen activator have focused on prehospital and hospital barriers with many successful strategies outlined in initiatives, such as Target: Stroke. • Methods for continuous quality improvement such as Six Sigma and Lean have been traditionally adopted for stroke process improvement.
WHAT THE STUDY ADDS
• We demonstrate the use of conducting an in-depth risk analysis using a Failures Modes, Effects and Criticality Analysis of the door-to-needle process at an academic medical center and at a community hospital to reveal system and operational barriers. • Although common failures were observed at the 2 hospitals and could lead to a generalizable redesign and intervention, differences were also noted, suggesting that individualized risk assessment should be conducted at every hospital to uncover unique barriers and to develop targeted solutions.
care at the CH (Table 1 ). In addition, fewer hierarchical barriers between nurses and physicians, nonmandatory involvement of a stroke neurologist (usually by telephone), but more physical and transportation issues because of the layout of the ED were identified at the CH compared with the AMC. We detected a total of 50 DTN process steps at the CH and 42 DTN process steps at the AMC. Most process steps at the CH and AMC were concentrated in the diagnosis phase of care (phase 4), 36% and 50%, respectively. Process steps in phases of care 1 to 3 (ie, patient prearrival, patient arrival to ED [door], and patient assessment) combined represented 40% and 38% for CH and AMC DTN processes (Figures I and II in the Data Supplement).
We detected a total of 70 failures at the CH compared with 76 failures at the AMC (Tables I and II in the Data Supplement) . At the CH, 23 (33%) failures were critical (resulting in >10 minute delay), whereas 34 (44.7%) were critical at the AMC. Table 2 lists the highest (top 20%) ranked failures at each site (rankings 1-7). At the CH, the highest 3 failures by criticality were (1) delay in registration because of ED overcrowding, (2) incorrect triage diagnosis among walk-in patients, and (3) delay in obtaining consent for thrombolytic treatment. The most critical failures at the AMC were (1) incorrect triage diagnosis among walk-in patients, (2) delay in stroke team activation, and (3) delay in obtaining CT imaging. In terms of phases of care, the most critical failure (incorrect triage diagnosis among walk-in patients) occurred in phase 2, for both institutions. The next most critical failures (ranks 2-5) occurred in phases 2 and 5 at the CH and phases 3 and 4 at the AMC.
There were several common themes at both the hospitals, particularly among walk-in patients. These, included delay in recognizing AIS symptoms and incorrect assessment at triage, because of anchor bias (eg, age), patients presenting with multiple health conditions, conducting assessment by memory versus following an assessment tool, and vague or atypical symptomatology (eg, dizziness, confusion, and syncope) requiring a complete neurological examination for recognition. Examples of unique failures at the CH included EMS having to wait for registration because of ED overcrowding during peak hours, the absence of greeters during off-shift hours, delay in recognition of stroke symptoms at triage because of nurse and physician workload during peak hours, and delays in obtaining consent because of inconsistent delivery of information to patient or family member. At the AMC, unique failures included delay in activation of the stroke team by nurses because of hierarchical barriers and delay in obtaining CT imaging because of lack of a quick-registration process.
For each FMECA, we estimate that healthcare provider participation required a minimum of 75 man-hours, including participation by a lead attending physician and 10 to 15 other clinicians and staff involved in the DTN process. These hours were spent as follows: (1) participation in group moderated sessions or follow-up individual interviews to describe the DTN process and failures; (2) data review to estimate frequencies or confirm anecdotal responses; and (3) review and validation of results. In addition to clinicians' participation hours, at least 140 man-hours of nonclinical staff were required to conduct the FMECA, including participation of a quality engineering professional, 2 research staff members or project coordinators, and 1 additional process stakeholder.
Discussion
Although best practices have been developed to achieve DTN time ≤60 minutes, critical failures in processes and systems of care for patients with AIS persist. Many of these failures relate to vulnerabilities in the diagnostic and communications systems, which are less standardized in DTN care. Our findings reflect opportunities to further reduce delays in steps that book-end the DTN process, including timely diagnosis and informed consent before treatment. Both of these steps involve provider-patient/family communications, while also encompassing issues, such as the role of the clinician, language barriers, cultural hierarchies, and framing bias. Although these failures probably result in significant treatment delays, they have been underevaluated and underemphasized in previous DTN quality improvement initiatives, and may require more complex solutions than sharing best practices, alone.
Given the time-sensitive nature of stroke thrombolysis, accurate and timely diagnosis is the first, highly critical step. Delays in diagnosis can lead to lack of efficacy and even result in harm such as thrombolysis-related hemorrhage, or lead to misdiagnosis and lack of treatment altogether. The stroke diagnostic system involves many subsystems (eg, clinical evaluation expertise, experience, knowledge, and availability of appropriate medical imaging). For example, acquiring critical information, a task that is influenced by knowledge and experience of the healthcare provider (eg, timing of onset of symptoms from patients or families) and diagnostic assessment subsystems (eg, neurological examination skills) may alter the frame. Framing bias or blindness can be a problem in any field of inquiry with the first step of framing being perhaps the most important and potentially dangerous. Similarly, anchoring, by honing in on presenting features early in the diagnostic process and failing to adjust when presented with new information, can lead to misdiagnosis. 25 Adoption of advances in information sciences, improved access to data, and innovations in clinical testing and diagnostic imaging integration are key factors to improving diagnostic accuracy and timeliness. 26 However, electronic health records still need to evolve considerably to facilitate the real-time decision support and synthesis of data to put it all together. 27 For example, standardized screening tools could be optimized to assist with recognition of stroke at triage, in particular, for walk-in patients. 28 Although DTN times have been reduced significantly in the United States, they remain inferior to the Helsinki and Melbourne experiences. A stated advantage of the Helsinki model is, however, direct communication between the stroke team and prehospital paramedics, which aid in early and accurate documentation of symptoms, signs, and time of onset. 8, 9 Beyond prenotification, emergency access to patient health records, as in Helsinki, might aid in more accurate diagnosis and decrease delays in DTN time by 
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facilitating confirmation of key historical data (eg, medications, recent surgeries, or bleeding) because these may be time consuming and difficult to collect from a patient with stroke, who is aphasic or who is unaccompanied by family members. Delays in informed consent were cited at the CH as occurring more often than at the AMC. It is noteworthy that the AMC stroke program policy permits stroke thrombolysis in the absence of written informed consent, consistent with American Heart Association/American Stroke Association guidelines and studies of presumed patient wishes, 5, 29, 30 whereas at the CH, written informed consent was required by local legal standards. Furthermore, the process of obtaining informed consent varied significantly, such that the CH relegated much of the task to the nurses with physicians playing a hands-off, wait-and-see supportive role, whereas at the AMC, standardized consent cards are distributed to neurology and ED teams as a visual aid during discussion with patients and families. Visual aids have been shown to assist in consent process for stroke. 31 Nevertheless, more formal guidance is needed to assist practitioners in obtaining informed consent for stroke thrombolysis in the emergency setting without causing unnecessary delays in treatment. 32, 33 Although the identification of common critical failures between academic and CHs suggests an opportunity for a generalizable redesign of the systems and processes of stroke care, this study also suggests that differences in the criticality and nature of failures must also be addressed at the individual hospital level, to develop robust, sustainable solutions to improve DTN time. Given the resource and spatial differences at these 2 urban institutions, redesigns will also necessarily need to account for the constraints and compromises of practical, reality-based solutions, rather than a one size fits all approach. For example, overcrowding in the CH will require a different redesign approach than at the AMC because hiring resources may be more limited. Potential solutions may include (1) creating a visual system for clinicians about the condition of arriving EMS patients (eg, AIS diagnosis and severity and time of onset); (2) adding a time tracker as a visual aid, which starts as soon as EMS arrives; or (3) allowing paramedics to participate in stroke team activities, such as electronic patient registration and transfer to CT. An explicit benefit of FMECA methodology is its focus on safety and prospective identification of failures. Although process improvement efforts usually focus on the desired outcome, they rarely focus on unintended consequences or address patient safety as a priority. For example, it is possible that an abbreviated evaluation, in the effort to reduce overall DTN time, may, unintentionally, increase the rate of misdiagnosis. Clinical evaluation to distinguish stroke from nonstroke mimics relies heavily on historical details and examination findings. As a result, errors can occur in ≤25% of patients with stroke overall, although the probability is lower in patients eligible for tPA. [34] [35] [36] [37] [38] Treatment with tPA in stroke mimics has been associated with a 1% risk of brain hemorrhage. 38 However, we recently noted an increase in stroke mimic thrombolysis at the AMC after a traditional quality improvement initiative that used the Define-Measure-Analyze-Improve-Control approach for Target Stroke best practice implementation. 39 Unintended adverse events ranged from minor (eg, gum bleeding) in several patients to significant extracranial bleeding (eg, spinal cord hematoma) in 1 patient. Another potential safety concern relates to errors in tPA dosing. When efforts to reduce delays overlook accuracy of weight in favor of speedy delivery of the drug, both underdosing (ie, decreased efficacy) and overdosing (ie, increased bleeding risk) may occur. [40] [41] [42] [43] [44] There are several limitations of our study. First, although we included both an AMC and a CH, generalizability is limited to urban settings and stroke center hospitals. The failures, their frequencies, severity, and criticality may vary by hospital and, therefore, affect the prioritization of failures. Furthermore, the studied hospitals may have higher performance in DTN care than the national average and, thus, the identified failures may not be generalizable to other settings. Second, although we used a comprehensive approach to elicit diverse stakeholder and care provider involvement during the study sessions, convenience sampling probably omitted some perspectives because of scheduling conflicts. Third, although moderators encouraged discussion during the sessions and relied on recall of experiences and personal attestation to outline the process steps and to inform frequency estimates, the information is certainly not comprehensive. To partially mitigate this limitation, we also corroborated frequencies with operational data, whenever available. Fourth, we simplified the severity score estimate by defining each score as an interval of DTN time delay (ie, 1-4 minutes and 5-9 minutes). Nevertheless, it is possible that participants overestimated or underestimated the severity of a failure.
Finally, although modest remuneration was provided to compensate participants, we cannot estimate whether the FMECA could have been conducted within the constraints of the providers' busy schedules without this gesture. However, participants spent, 4 hours during 2 sessions, on average, which seems to be a modest and feasible time commitment to conduct a quality improvement initiative. The man-hours required to complete an FMECA can vary greatly depending on factors, such as the scope of the project, leaders' familiarity with the methodology, and ability of the team to obtain data for the estimation of frequencies of failures. Since, in this study, nonclinical staff members were familiar with FMECA methodology, no additional training hours were necessary. However, additional training hours may be necessary for staff looking to implement FMECA methodology for the first time. We recommend FMECA training for at least the lead quality professional because of conducting an FMECA.
Conclusions
This article highlights the usefulness of the FMECA methodology to examine DTN care for patients experiencing symptoms of AIS. This study identified several key failures in academic and CH settings that may provide further opportunities for reductions in DTN time, despite previous implementation of best practices in national and international DTN programs. This study suggests that future initiatives should focus on early and accurate identification of AIS symptoms, rapid and accurate documentation of stroke onset, expedited diagnosis, and improved processes for obtaining informed consent. On the basis of the findings of this study, we recommend, however, that hospitals create their own process maps and identify and characterize the failures in their systems and processes of care. Gaining an understanding of hospital-specific failures and their unique characteristics (eg, frequency, harm, and safeguards) will lead to better targeted interventions. Continual quality improvement within an integrated stroke system of care using these novel approaches may aid hospitals in further reducing DTN time.
